SG10201913927VA - Kinase inhibitors and uses thereof - Google Patents
Kinase inhibitors and uses thereofInfo
- Publication number
- SG10201913927VA SG10201913927VA SG10201913927VA SG10201913927VA SG10201913927VA SG 10201913927V A SG10201913927V A SG 10201913927VA SG 10201913927V A SG10201913927V A SG 10201913927VA SG 10201913927V A SG10201913927V A SG 10201913927VA SG 10201913927V A SG10201913927V A SG 10201913927VA
- Authority
- SG
- Singapore
- Prior art keywords
- kinase inhibitors
- kinase
- inhibitors
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/04—Seven-membered rings having the hetero atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507698P | 2017-05-17 | 2017-05-17 | |
| US201862664895P | 2018-04-30 | 2018-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913927VA true SG10201913927VA (en) | 2020-03-30 |
Family
ID=64274744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913927VA SG10201913927VA (en) | 2017-05-17 | 2018-05-17 | Kinase inhibitors and uses thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11203600B2 (en) |
| EP (1) | EP3624797A4 (en) |
| JP (2) | JP7064512B2 (en) |
| KR (1) | KR102638151B1 (en) |
| CN (1) | CN110913858A (en) |
| AU (1) | AU2018269743B2 (en) |
| BR (1) | BR112019023918A2 (en) |
| CA (1) | CA3063934A1 (en) |
| CL (1) | CL2019003263A1 (en) |
| CO (1) | CO2019012957A2 (en) |
| CR (1) | CR20190566A (en) |
| DO (1) | DOP2019000290A (en) |
| EC (1) | ECSP19089214A (en) |
| IL (1) | IL270648B2 (en) |
| MX (2) | MX2019013645A (en) |
| PE (1) | PE20200729A1 (en) |
| PH (1) | PH12019550235A1 (en) |
| SG (1) | SG10201913927VA (en) |
| TW (1) | TWI794232B (en) |
| WO (1) | WO2018213632A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7273954B2 (en) | 2018-10-19 | 2023-05-15 | ディスアーム セラピューティクス， インコーポレイテッド | Inhibition of SARM1 in combination with NAD+ or NAD+ precursors |
| WO2021187605A1 (en) * | 2020-03-19 | 2021-09-23 | 田辺三菱製薬株式会社 | NITROGEN-CONTAINING HETEROCYCLIC α-CYANO CARBONYL COMPOUND |
| TW202214617A (en) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | Isoxazolidines as ripk1 inhibitors and use thereof |
| KR200493347Y1 (en) | 2020-07-06 | 2021-03-17 | 박혜진 | Easy to carry mask |
| TW202302565A (en) * | 2021-02-19 | 2023-01-16 | 英商卡爾維斯塔製藥有限公司 | Enzyme inhibitors |
| US11897876B2 (en) | 2021-11-11 | 2024-02-13 | Genzyme Corporation | Isoxazolidines as RIPK1 inhibitors and use thereof |
| WO2024025817A1 (en) * | 2022-07-25 | 2024-02-01 | Denali Therapeutics Inc. | Solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5- dihydro-2h-pyrido[3,4-f][l,4]oxazepine-9-carbonitrile |
| WO2024044151A1 (en) * | 2022-08-23 | 2024-02-29 | Genzyme Corporation | Methods for treating receptor-interacting protein kinase 1-mediated diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3861187B2 (en) * | 1996-08-02 | 2006-12-20 | 住友精化株式会社 | Method for producing thiazepine derivatives |
| SK3632003A3 (en) | 2000-09-27 | 2003-09-11 | Ajinomoto Kk | Benzodiazepine derivatives, pharmaceutical composition comprising same and their use |
| RU2456287C1 (en) * | 2011-05-20 | 2012-07-20 | Николай Филиппович Савчук | Incretin secretagogues, methods for preparing and applying them |
| UY34171A (en) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | FUSIONED HETEROCYCLIC COMPOUNDS AS IONIC CHANNEL MODULATORS |
| TWI648274B (en) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | Heterocyclic guanamines as kinase inhibitors (2) |
| CN104059068B (en) | 2013-03-20 | 2017-02-08 | 中国科学院上海药物研究所 | Beta-amino-carbonyl compound, preparation method, its pharmaceutical composition and application thereof |
| MX2020003488A (en) * | 2015-02-02 | 2022-05-24 | Forma Therapeutics Inc | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors. |
| UY36680A (en) * | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | HETEROCYCLIC AMIDES AS QUINASA INHIBITORS |
| CN108112251B (en) * | 2015-06-15 | 2021-03-05 | 葛兰素史克知识产权发展有限公司 | NRF2 modulators |
-
2018
- 2018-05-17 KR KR1020197036911A patent/KR102638151B1/en active IP Right Grant
- 2018-05-17 PE PE2019002424A patent/PE20200729A1/en unknown
- 2018-05-17 MX MX2019013645A patent/MX2019013645A/en unknown
- 2018-05-17 TW TW107116834A patent/TWI794232B/en active
- 2018-05-17 BR BR112019023918-9A patent/BR112019023918A2/en unknown
- 2018-05-17 JP JP2019563596A patent/JP7064512B2/en active Active
- 2018-05-17 CA CA3063934A patent/CA3063934A1/en active Pending
- 2018-05-17 CN CN201880047293.5A patent/CN110913858A/en active Pending
- 2018-05-17 WO PCT/US2018/033266 patent/WO2018213632A1/en unknown
- 2018-05-17 SG SG10201913927VA patent/SG10201913927VA/en unknown
- 2018-05-17 CR CR20190566A patent/CR20190566A/en unknown
- 2018-05-17 AU AU2018269743A patent/AU2018269743B2/en active Active
- 2018-05-17 EP EP18802127.3A patent/EP3624797A4/en active Pending
- 2018-05-17 IL IL270648A patent/IL270648B2/en unknown
-
2019
- 2019-11-13 PH PH12019550235A patent/PH12019550235A1/en unknown
- 2019-11-14 CL CL2019003263A patent/CL2019003263A1/en unknown
- 2019-11-14 MX MX2022010755A patent/MX2022010755A/en unknown
- 2019-11-14 US US16/684,340 patent/US11203600B2/en active Active
- 2019-11-14 DO DO2019000290A patent/DOP2019000290A/en unknown
- 2019-11-19 CO CONC2019/0012957A patent/CO2019012957A2/en unknown
- 2019-12-16 EC ECSENADI201989214A patent/ECSP19089214A/en unknown
-
2021
- 2021-09-09 JP JP2021146775A patent/JP7241825B2/en active Active
- 2021-10-26 US US17/511,193 patent/US20220041620A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110913858A (en) | 2020-03-24 |
| KR20200006125A (en) | 2020-01-17 |
| CO2019012957A2 (en) | 2020-05-29 |
| TWI794232B (en) | 2023-03-01 |
| AU2018269743A1 (en) | 2020-01-16 |
| US20220041620A1 (en) | 2022-02-10 |
| CL2019003263A1 (en) | 2020-04-17 |
| WO2018213632A1 (en) | 2018-11-22 |
| TW201900618A (en) | 2019-01-01 |
| JP7241825B2 (en) | 2023-03-17 |
| IL270648B1 (en) | 2023-11-01 |
| PE20200729A1 (en) | 2020-07-23 |
| IL270648A (en) | 2020-01-30 |
| CR20190566A (en) | 2020-06-14 |
| JP7064512B2 (en) | 2022-05-10 |
| EP3624797A4 (en) | 2021-07-21 |
| IL270648B2 (en) | 2024-03-01 |
| PH12019550235A1 (en) | 2020-07-20 |
| ECSP19089214A (en) | 2020-05-29 |
| CA3063934A1 (en) | 2018-11-22 |
| AU2018269743B2 (en) | 2024-01-11 |
| JP2021193116A (en) | 2021-12-23 |
| US11203600B2 (en) | 2021-12-21 |
| EP3624797A1 (en) | 2020-03-25 |
| MX2019013645A (en) | 2020-09-17 |
| JP2020520924A (en) | 2020-07-16 |
| US20200087319A1 (en) | 2020-03-19 |
| BR112019023918A2 (en) | 2020-06-02 |
| MX2022010755A (en) | 2022-09-23 |
| KR102638151B1 (en) | 2024-02-16 |
| DOP2019000290A (en) | 2020-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271999A (en) | Tyk2 inhibitors and uses thereof | |
| IL265922A (en) | Tyk2 inhibitors and uses thereof | |
| IL266109A (en) | Tyk2 inhibitors and uses thereof | |
| ZA201707423B (en) | Imidazolonyl quinolines and use thereof as atm kinase inhibitors | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| EP3171874A4 (en) | Imidazolyl kinase inhibitors and uses thereof | |
| IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| PT3621694T (en) | Lrrc33 inhibitors and use thereof | |
| IL274207A (en) | Aminoimidazopyridazines as kinase inhibitors | |
| IL262400A (en) | Erbb inhibitors and uses thereof | |
| GB201705201D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201609580D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201505975D0 (en) | Inhibitors and their uses | |
| GB201505971D0 (en) | Inhibitors and their uses |